Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Opinion: Discussing the standard of care and/or the potential of Vabysmo (faricimab-svoa) and the recent label expansion approved by the FDA to include treatment of RVO

Ticker(s): RHHBY, REGN

Who's the expert?

Institution: Private Practice

Manages 30 - 40 patients weekly with diabetic macular edema
Clinical interest in the medical and surgical treatment of diabetic retinopathy, complex retinal detachments, and secondary intraocular lens surgery
Authored numerous articles in peer-reviewed journals as well as a textbook highlighting retinal genetic diseases.

Interview Goal

This interview will focus on the the potential of Vabysmo (faricimab-svoa) and the two phase 3 trials (BALATON and COMINO), which formed the basis of the FDA’s decision to expand the label for Vabysmo to include RVO.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.